Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Up 11.4% in October

Harvard Bioscience, Inc. (NASDAQ:HBIO) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 350,600 shares, a growth of 11.4% from the September 30th total of 314,700 shares. Based on an average daily volume of 110,600 shares, the short-interest ratio is currently 3.2 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HBIO. Allspring Global Investments Holdings LLC acquired a new stake in shares of Harvard Bioscience during the 2nd quarter valued at about $31,000. SG Americas Securities LLC acquired a new stake in Harvard Bioscience in the third quarter valued at approximately $36,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Harvard Bioscience in the second quarter valued at approximately $40,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Harvard Bioscience in the first quarter valued at approximately $54,000. Finally, Brighton Jones LLC acquired a new position in shares of Harvard Bioscience during the 3rd quarter worth approximately $68,000. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Stock Performance

Shares of HBIO traded down $0.10 during mid-day trading on Thursday, reaching $2.35. The company had a trading volume of 62,683 shares, compared to its average volume of 113,688. The stock has a market capitalization of $102.06 million, a P/E ratio of -11.90 and a beta of 1.29. Harvard Bioscience has a 52-week low of $2.30 and a 52-week high of $5.56. The stock has a 50 day moving average of $2.65 and a two-hundred day moving average of $3.02. The company has a quick ratio of 0.94, a current ratio of 2.05 and a debt-to-equity ratio of 0.48.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.06). The company had revenue of $23.10 million during the quarter, compared to analysts’ expectations of $29.91 million. Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. On average, analysts expect that Harvard Bioscience will post 0.11 earnings per share for the current year.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.